1. Background {#sec128144}
=============

The highest rates of primary liver cancer are found in East and South-East Asia. Hepatocellular carcinoma (HCC) is the primary histological type of hepatic carcinoma, accounting for 85 - 90% of the total burden of liver cancer all over the world ([@A32145R1], [@A32145R2]). The occurrence and death rate of HCC are almost the same as its high lethality rate ([@A32145R2]). The onset of HCC has a multi-factorial and multi-stage course, involving both hereditary and environmental factors. The long-term carcinogenic effects give rise to genetic changes, which can lead to tumor formation ([@A32145R3]). It is necessary to search for hereditary factors, which could help us detect the population at highest risk and better regulate the screening procedures. Besides, the recognition of risk factors could lead to better diagnoses and planning of novel prevention measures for high-risk individuals ([@A32145R4]).

As an anti-oncogene, the Ras association domain family 1A gene (RASSF1A) has been reported to play a vital role in the maintenance of genomic instability; it controls a sequence of vital cellular functions in the integration of signaling pathways ([@A32145R5]-[@A32145R9]). The loss of expression by promoter methylation of RASSF1A is one of the most common early events in HCC that plays an important role in tumorigenesis and metastasis of HCC ([@A32145R10], [@A32145R11]). The most widespread form of human genetic variation is single nucleotide polymorphism (SNP), which may contribute to tumor sensitivity. To date, many studies have demonstrated that SNPs of RASSF1A are associated with the risk of many types of cancers, including breast cancer ([@A32145R12]-[@A32145R15]), lung cancer ([@A32145R16], [@A32145R17]), esophageal cancer ([@A32145R16], [@A32145R18]), head and neck cancer ([@A32145R16]), colorectal cancer ([@A32145R16]), renal cell carcinoma ([@A32145R19]), HCC ([@A32145R20]), gastric cancer ([@A32145R18]), and prostate cancer ([@A32145R21]). It has been proven that guanine (G)/thymine (T) SNP at the first position of codon 133 in exon 3 of RASSF1A (dbSNP ID: rs2073498), leads to the replacement of an Ala residue (GCT) through the Ser residue (TCT) in the ataxia telangiectasia mutated (ATM) phosphorylated position, and can impact the function of RASSF1A ([@A32145R22], [@A32145R23]). However, the results of these studies have been controversial ([@A32145R12]-[@A32145R20]). This is because the frequency of the Ser allele of RASSF1A Ala133Ser polymorphism varies in different geographic areas and ethnic populations ([@A32145R24]).

The Qidong county of Nantong city is one of the regions with the highest incidence of HCC in China ([@A32145R25]). In the recent years, several studies have investigated the correlation between genetic polymorphisms, methylation and HCC. Nevertheless, the effects of RASSF1A Ala133Ser polymorphism and methylation on HCC have not been well identified in Nantong.

Determining the molecular spectroscopy of HCC is essential as it could help us recognize molecular biomarkers for the screening of at-risk individuals and achieve early detection.

2. Objectives {#sec128145}
=============

A hospital-based case control research including 260 HCC cases and 235 controls was carried out to investigate the impact of RASSF1A Ala133Ser polymorphism and promoter methylation on HCC, and its prognostic and functional implications in subjects from a high incidence area in Nantong.

3. Patients and Methods {#sec128150}
=======================

3.1. Study Population {#sec128146}
---------------------

The tumor and corresponding peri-tumorous normal tissues were obtained from 260 HCC patients whose frozen tumor samples had been collected from an affiliated hospital of Nantong University, from March 2007 to December 2012. In addition, 235 non-cancer subjects from the same hospital were treated as normal controls and matched according to their age, gender and ethnicity. We gathered 5 mL of pre-operation peripheral blood samples from each of the selected patients and control subjects in succession. Before the surgery, the patients were not treated by radiation, chemical or immunization therapy. The average age of the patients at the time of surgery was 53.6 years. Additional clinical data were recorded and are presented in [Table 1](#tbl33156){ref-type="table"}. We confirmed the tumor stage in accordance with the barcelona clinic liver cancer (BCLC) staging system ([@A32145R26]). Written informed consents and any related pictures were obtained from each patient prior to publication of this study. We received an ethics approval to do this research from the Human Research Ethics Committee of Nantong University affiliated hospital, Jiangsu province, China. Overall survival of these 260 patients was followed until July 31st, 2013. During the final follow-up, the data of surviving patients without symptoms of disease was examined.

###### The Genotyping of Ala133Ser in RASSF1A Gene in Patients With Hepatocellular Carcinoma and Normal Controls

  Genotyping               Control ^[a](#fn34725){ref-type="table-fn"}^   HCC ^[a](#fn34725){ref-type="table-fn"}^   P          OR      95% CI
  ------------------------ ---------------------------------------------- ------------------------------------------ ---------- ------- ----------------
  **Allele frequency**                                                                                                                  
  Ala                      445 (94.7)                                     452 (86.9)                                                    
  Ser                      25 (5.3)                                       68 (13.1)                                  \< 0.001   2.678   1.662 - 4.314
  **General genotype**                                                                                                                  
  Ala/Ala                  211 (89.8)                                     200 (76.9)                                                    
  Ala/Ser                  23 (9.8)                                       52 (20.0)                                  0.001      2.385   1.407 - 4.042
  Ser/Ser                  1 (0.4)                                        8 (3.1)                                    0.017      8.440   1.046 - 68.089
  **Dominant genotype**                                                                                                                 
  Ala/Ala                  211 (89.8)                                     200 (76.9)                                                    
  Ala/Ser + Ser/Ser        24 (10.2)                                      60 (23.1)                                  \< 0.001   2.638   1.582 - 4.398
  **Recessive genotype**                                                                                                                
  Ala/Ala + Ala/Ser        234 (99.6)                                     252 (96.9)                                                    
  Ser/Ser                  1 (0.4)                                        8 (3.1)                                    0.027      7.429   0.922 - 59.847

^a^Data are presented as No. (%).

3.2. Sequencing Analysis for Genotyping {#sec128147}
---------------------------------------

Using the phenol/chloroform extraction method, genomic DNA was extracted from ambient blood plasma. The polymerase chain reaction (PCR) was carried out in a 50-μL reaction mixture, which contained 1 μL of genomic DNA, 10 mM dNTP, 10X buffered solution, 10 μM up and down treating agents (separately), and 1 U Taq DNA polymerase. The reagents for this study were purchased from TaKaRa in Beijing city, China. The sequences of the outside and inside primers were as follows: 5-'GCCAAATGATTCTGTCTTTCCCT forward and 5'-CAAGATAACCTCAGTTGTGACCCTC reverse. We used the GeneAmp RCR system 9700 gene magnifier (ABI, California, USA) to establish the conditions as follows: five minutes of pre-degeneration at 95°C; then 30 seconds of 30 cycles at 95°C, 30 seconds at 58°C and 30 seconds at 68°C; followed by 10 minutes of extension at 68°C. The purified PCR product was recovered according to the instructions in the PCR Purification Kit (Axygen, California, USA). After sequencing, the basic local alignment search tool (BLAST) was used to test and compare the results with Genbank.

3.3. Methylation-Specific Polymerase Chain Reaction (MSP) {#sec128148}
---------------------------------------------------------

Genomic DNA was isolated from frozen tissue specimens and cell lines by RNase treatment, phenol/chloroform extraction and ethanol precipitation. The bisulﬁte modiﬁcations of DNA and MSP were performed as described previously ([@A32145R27]). Two cell lines, Hep3B (HCC cell line) and L0~2~ (normal liver cell line), from the Chinese National Human Genome Center (Shanghai, China), were used as positive controls for methylated and un-methylated DNA. A ddH~2~O blank served as the negative control. Methylated samples were defined by the presence of methylated PCR products.

3.4. Statistical Analysis {#sec128149}
-------------------------

The statistical comparisons were performed by the χ^2^ test using the SPSS 19.0 software (SPSS, Chicago, USA). The expected genotype frequencies measured by the Hardy-Weinberg equilibrium theory were used to compare the results with observed values. The odds ratios (ORs) and 95% confidence intervals (CIs) from the binary logistic regression analysis were used to estimate the associations between RASSF1A Ala133Ser genotypes and the risk of HCC. Survival curves were calculated by the Kaplan-Meier method. The factors of prognostic significance were successively investigated with the univariate and multivariate Cox regression model. For all tests, the significance level for statistical analysis was set at P \< 0.05.

4. Results {#sec128154}
==========

4.1. Genotype Frequency Distribution of RASSF1A Ala133Ser Polymorphism in Hepatocellular Carcinoma {#sec128151}
--------------------------------------------------------------------------------------------------

Peripheral blood plasmas taken from 235 controls and 260 HCC subjects were analyzed for the existence of Ala133Ser ([Figure 1](#fig24405){ref-type="fig"} and [Table 1](#tbl33156){ref-type="table"}). The genotypic frequencies of the HCC patients (n = 260, χ^2^= 3.760, P = 0.153) and controls (n = 235, χ^2^ = 0.188, P = 0.910) were both in the Hardy-Weinberg equilibrium. The results showed no population stratification and no sampling bias. There was a significant difference in the RASSF1A Ale133Ser T allele (Ala/Ser and Ser/Ser) genotype between the HCC patients and control subjects (23.1% vs. 10.2%, P \< 0.001). With the Ala/Ala genotype as the reference, the Ala/Ser genotype increased the risk of HCC (OR = 2.385, 95% CI = 1.407 - 4.042, P = 0.001). Besides, in comparison with the Ala/Ala genotype, cases carrying the Ser/Ser genotype had an 8.440-fold increase in the risk of HCC (95% CI = 1.046 - 68.089, P = 0.017). Furthermore, Ser was found to have a significant gene dosage effect. With the Ala/Ala genotype as the reference, the OR for the T allele genotype was 2.638 (95% CI = 1.582 - 4.398, P \< 0.001). Compared with the homozygote Ala/Ala and heterozygote Ala/Ser carriers, there was a significant increase in the risk of HCC in subjects with the homozygote variant of Ser/Ser of RASSF1A Ala133Ser polymorphism (OR = 7.429, 95% CI = 0.922 - 59.847, P = 0.027). The Ser frequency of RASSF1A Ala133Ser polymorphism in cases with HCC was significantly higher compared with the healthy control subjects (5.3% vs. 13.1%, P \< 0.001). Furthermore, the Ala/Ala genotype in HCC peripheral blood plasma with hepatocirrhosis was more risky for patients with HCC than for healthy controls (OR = 10.189, 95% CI = 2.403 - 43.203, P \< 0.001) ([Table 2](#tbl33157){ref-type="table"}).

![Sequencing Analysis of RASSF1A in Probands\
Three representative sets of sequencing data are shown. (A) Ser/Ser genotype; (B) Ala/Ser genotype; (C) Ala/Ala genotype.](hepatmon-15-10-32145-i001){#fig24405}

###### The Correlation Between RASSF1A Ala133Ser Polymorphism and Suspected Risk Factors^[a](#fn34726){ref-type="table-fn"}^

  Parameters                Total   RASSF1A Ala133Ser Polymorphism ^[b](#fn34727){ref-type="table-fn"}^   P Value ^[c](#fn34728){ref-type="table-fn"}^   
  ------------------------- ------- --------------------------------------------------------------------- ---------------------------------------------- ----------
  **Age, y**                                                                                                                                             0.147
  ≤ 55                      126     92 (73.0)                                                             34 (27.0)                                      
  \> 55                     134     108 (80.6)                                                            26 (19.4)                                      
  **Gender**                                                                                                                                             0.210
  Male                      144     115 (79.9)                                                            29 (20.1)                                      
  Female                    116     85 (73.3)                                                             31 (26.7)                                      
  **Hepatocirrhosis**                                                                                                                                    \< 0.001
  Negative                  54      52 (96.3)                                                             2 (3.7)                                        
  Positive                  206     148 (71.8)                                                            58 (28.2)                                      
  **AFP, μg/L**                                                                                                                                          0.867
  ≤ 20                      54      42 (77.8)                                                             12 (22.2)                                      
  \> 20                     206     158 (76.7)                                                            48 (23.3)                                      
  **Tumor size, cm**                                                                                                                                     0.288
  ≤ 3                       167     125 (74.9)                                                            42 (25.1)                                      
  \> 3                      93      75 (80.6)                                                             18 (19.4)                                      
  **BCLC stage**                                                                                                                                         0.559
  A                         198     154 (77.8)                                                            44 (22.2)                                      
  B + C + D                 62      46 (74.2)                                                             16 (25.8)                                      
  **Edmondson division**                                                                                                                                 0.061
  G1                        42      37 (88.1)                                                             5 (11.9)                                       
  G2-4                      218     163 (74.8)                                                            55 (25.2)                                      
  **HBV**                                                                                                                                                0.978
  Negative                  56      43 (76.8)                                                             13 (23.2)                                      
  Positive                  204     157 (77.0)                                                            47 (23.0)                                      
  **Cigarette smoking**                                                                                                                                  0.064
  Non-smoker                91      64 (70.3)                                                             27 (29.7)                                      
  Smoker                    169     136 (80.5)                                                            33 (19.5)                                      
  **Alcohol consumption**                                                                                                                                0.812
  Non-drinker               90      70 (77.8)                                                             20 (22.2)                                      
  Drinker                   170     130 (76.5)                                                            40 (23.5)                                      

^a^Abbreviations: AFP: α-Fetoprotein; BCLC: Barcelona Clinic Liver Cancer staging system; HBV: hepatitis virus B; RASSF1A: Ras association domain family 1A gene.

^b^Data are presented as No. (%).

^c^P Values less that 0.05 were considered significant.

4.2. The Methylation of RASSF1A in Hepatocellular Carcinoma {#sec128152}
-----------------------------------------------------------

The frequency of RASSF1A methylation in HCC was 2.14 folds higher than the adjacent normal tissue (214/260, 82.3% vs. 101/260, 38.8%, P \< 0.001). It also increased the risk of developing HCC by 7.324 folds (OR = 7.324, 95% CI = 4.887 - 10.975, P \< 0.001) ([Figure 2](#fig24406){ref-type="fig"}). Furthermore, the RASSF1A methylation ratio of G2-4 Edmondson division was significantly higher than that of G1 Edmondson division in HCC patients (OR = 2.165, 95% CI = 1.009 - 4.642, P = 0.044) ([Table 3](#tbl33158){ref-type="table"}).

![Methylation-Specific Polymerase Analysis of the RASSF1A Gene in Hepatocellular Carcinoma\
Representative MSP results of the three HCC and paired adjacent normal tissues (T~26~N~26~, T~87~N~87~ and T~152~N~152~). ddH~2~O was used as the negative control. Hep3B cells lines (methylated positive control) and L0~2~ (unmethylated positive control) were used. NL: normal liver tissue. T: HCC tissue. N: corresponding adjacent normal tissue. Lane M: indicates the presence of methylated genes; Lane U: indicates the presence of unmethylated genes.](hepatmon-15-10-32145-g001){#fig24406}

###### Correlation Between RASSF1A Methylation and Suspected Risk Factors^[a](#fn34729){ref-type="table-fn"}^

  Parameters                Total   RASSF1A Methylation Status ^[b](#fn34730){ref-type="table-fn"}^   P Value ^[c](#fn34731){ref-type="table-fn"}^   
  ------------------------- ------- ----------------------------------------------------------------- ---------------------------------------------- -------
  **Age, y**                                                                                                                                         0.924
  ≤ 55                      126     104 (82.5)                                                        22 (17.5)                                      
  \> 55                     134     110 (82.1)                                                        24 (17.9)                                      
  **Gender**                                                                                                                                         0.619
  Male                      116     97 (83.6)                                                         19 (16.4)                                      
  Female                    144     117 (81.2)                                                        27 (18.8)                                      
  **Hepatocirrhosis**                                                                                                                                0.075
  Negative                  54      40 (74.1)                                                         14 (25.9)                                      
  Positive                  206     174 (84.5)                                                        32 (15.5)                                      
  **AFP, μg/L**                                                                                                                                      0.306
  ≤ 20                      54      47 (87.0)                                                         7 (13.0)                                       
  \> 20                     206     167 (81.1)                                                        39 (18.9)                                      
  **Tumor size, cm**                                                                                                                                 0.123
  ≤ 3                       167     142 (85.0)                                                        25 (15.0)                                      
  \> 3                      93      72 (77.4)                                                         21 (22.6)                                      
  **BCLC stage**                                                                                                                                     0.439
  A                         198     165 (83.3)                                                        33 (16.7)                                      
  B + C + D                 62      49 (79.0)                                                         13 (21.0)                                      
  **Edmondson division**                                                                                                                             0.044
  G1                        42      30 (71.4)                                                         12 (28.6)                                      
  G2-4                      218     184 (84.4)                                                        34 (15.6)                                      
  **HBV**                                                                                                                                            0.971
  Negative                  56      46 (82.1)                                                         10 (17.9)                                      
  Positive                  204     168 (82.4)                                                        36 (17.6)                                      
  **Cigarette smoking**                                                                                                                              0.082
  Non-smoker                91      80 (87.9)                                                         11 (12.1)                                      
  Smoker                    169     134 (79.3)                                                        35 (20.7)                                      
  **Alcohol consumption**                                                                                                                            0.293
  Non-drinker               90      71 (78.9)                                                         19 (21.1)                                      
  Drinker                   170     143 (84.1)                                                        27 (15.9)                                      

^a^Abbreviations: AFP: α-Fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging system; HBV: hepatitis virus B; RASSF1A: Ras association domain family 1A gene.

^b^Data are presented as No. (%).

^c^P Values less that 0.05 were considered significant

4.3. Survival Analysis {#sec128153}
----------------------

Univariate and multivariate Cox regression analyses verified that hepatocirrhosis, BCLC stage, Edmondson division, RASSF1A methylation and Ala133Ser polymorphism were the strongest prediction factors of overall survival (P \< 0.05) ([Table 4](#tbl33159){ref-type="table"}). The Kaplan-Meier survival curves revealed that there was a significantly better prognosis for patients with HCC carrying the Ala/Ala genotype without hepatocirrhosis and RASSF1A methylation, but with early BCLC stage, well-Edmondson division ([Figure 3](#fig24407){ref-type="fig"}).

###### Univariate and Multivariable Analysis of Prognostic Factors for Overall Survival in Hepatocellular Carcinoma^[a](#fn34732){ref-type="table-fn"}^

  Variable                        Univariate Analysis       Multivariate Analysis                             
  ------------------------------- ------------------------- ----------------------- ------------------------- ----------
  **Age, y**                                                                                                  
  ≤ 55 vs. \> 55                  0.668 (0.430 - 1.039)     0.073                                             
  **Gender**                                                                                                  
  Male vs. female                 0.875 (0.579 - 1.324)     0.528                                             
  **Cigarette smoking**                                                                                       
  Non-smoker vs. smoker           0.963 (0.622 - 1.491)     0.866                                             
  **Alcohol consumption**                                                                                     
  Non-drinker vs. drinker         1.022 (0.648 - 1.612)     0.925                                             
  **HBV**                                                                                                     
  Negative vs. Positive           0.650 (0.371 - 1.138)     0.132                                             
  **AFP, μg/L**                                                                                               
  ≤ 20 vs. \> 20                  1.317 (0.792 - 2.190)     0.288                                             
  **Tumor size, cm**                                                                                          
  ≤ 3 vs. \> 3                    0.725 (0.445 - 1.181)     0.196                                             
  **Hepatocirrhosis**                                                                                         
  Negative vs. Positive           9.035 (2.782 - 29.345)    \< 0.001                7.728 (2.396 - 24.923)    0.001
  **BCLC stage**                                                                                              
  A vs. B + C + D                 10.166 (5.359 - 19.285)   \< 0.001                8.026 (4.693 - 13.725)    \< 0.001
  **Edmondson division**                                                                                      
  G1 vs. G2-4                     11.726 (5.036 - 27.302)   \< 0.001                11.306 (5.132 - 24.907)   \< 0.001
  **RASSF1A methylation**                                                                                     
  Negative vs. Positive           7.904 (2.352 - 26.567)    0.001                   8.341 (2.531 - 27.491)    \< 0.001
  **RASSF1A (Ala133Ser) SNP**                                                                                 
  Ala/Ala vs. Ala/Ser + Ser/Ser   8.519 (5.127 - 14.157)    \< 0.001                8.152i (5.045 - 13.173)   \< 0.001

^a^Abbreviations: AFP: α-Fetoprotein; BCLC: Barcelona Clinic Liver Cancer staging system; HBV: hepatitis virus B; RASSF1A: Ras association domain family 1A gene.

^b^P values less that 0.05 were considered significant.

![Kaplan-Meier Survival Analysis of Patients With Hepatocellular Carcinoma\
(A) The overall survival rate in patients with hepatocirrhosis was significantly lower than that in patients without hepatocirrhosis. (B) The overall survival rate in patients with G2-4 Edmondson divisions was significantly lower than that in patients with G1 Edmondson divisions. (C) The overall survival rate in patients with advanced BCLC stage was significantly lower than that in patients with early BCLC stage.(D) The overall survival rate in patients with RASSF1A methylation was significantly lower than that in patients without RASSF1A methylation. (E) The overall survival rate in patients with Ala/Ser and Ser/Ser genotype was significantly lower than that in patients with the Ala/Ala genotype.](hepatmon-15-10-32145-i002){#fig24407}

5. Discussion {#sec128155}
=============

In this study, we investigated whether the RASSF1A Ala133Ser polymorphism could have an impact on the susceptibility to HCC. To the best of our knowledge, this is the first epidemiological study to reveal the association between RASSF1A Ala133Ser polymorphism and HCC risk in China. Our results suggest that the Ser allele of RASSF1A significantly increases the risk of HCC. The RASSF1A Ala133Ser polymorphism is located in a putative ATM phosphorylation site consensus sequence ([@A32145R7], [@A32145R28]). The cell cycle checkpoint responses at G1, S and G2 are all remarkably abnormal in ATM deficient cells ([@A32145R29]). The Ser residue at the ATM site can be phosphorylated upon ionizing radiation and it can then induce cell death and suppress colony formation ([@A32145R30]). Due to the involvement of ATM in DNA damage control, patients with HCC carrying RASSF1A Ala133Ser polymorphisms may be resistant to radiation-based chemotherapy ([@A32145R31]). Therefore, it is reasonable to assume that subjects carrying the Ser allele of the RASSF1A Ala133Ser polymorphism may be susceptible to HCC. Knowledge about the mechanisms involved in HCC carcinogenesis may help identify targets for chemoprevention or therapeutic strategies.

The connection between RASSF1A Ala133Ser polymorphism and the risk of various cancers has been investigated by several studies ([@A32145R24]). In this study, the frequency of genotypes containing the Ser allele of RASSF1A Ala133Ser polymorphism is similar to the other Asian cancer types, yet lower than in Caucasian cancer types. The difference in results may be explained by the following points. First, different types of cancer may have different mechanisms of carcinogenesis. Second, the discrepancy could also be interpreted partially by the influence of the gene-environment interaction in a multistep process of carcinogenesis. Third, studies recruiting controls form hospital populations are more likely to acquire significant results in allele comparison, heterozygous and dominant genetic models. Fourth, different cancer risks were also found in the studies using different genotyping methods. In this study, we also investigated promoter methylation of RASSF1A in HCC. Our results suggest that RASSF1A methylation may be an early event in HCC carcinogenesis. Further studies are required to characterize RASSF1A methylation in HCC precancerous lesions.

In order to confirm whether RASSF1A methylation and its Ala133Ser polymorphism are risk-factors predicting shorter survival after surgery, we also analyzed the influence of methylation and Ala133Ser polymorphism on patient survival. The Kaplan-Meier analysis indicated that the life span of patients with RASSF1A methylation was shorter in comparison to that of patients lacking this genetic feature. Besides, for the first time, we found that HCC patients with the Ser allele of RASSF1A Ala133Ser polymorphism had significantly poorer overall survival in Nantong. Univariate and further multivariate analyses demonstrated that hepatocirrhosis, BCLC stage, Edmondson division, RASSF1A methylation and RASSF1A Ala133Ser polymorphism independently predicted the unfavorable overall survival of patients with HCC.

In conclusion, this was the first study to reveal that the RASSF1A Ala133Ser polymorphism might confer genetic susceptibility to HCC in the Chinese population. The Ser allele of RASSF1A Ala133Ser and RASSF1A promoter methylation could significantly increase the risk of HCC development. Of course, further work is necessary to illustrate the mechanism of RASSF1A in the development of HCC. The RASSF1A gene will be developed ultimately as one of the molecular biomarkers for high-risk subject screening and early detection of HCC in the future.
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